ArticlePlants (Basel, Switzerland)2022
Brevilin A Isolated from
Article in Plants (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Review
- Brevilin A Inhibits Prostate Cancer Progression by Decreasing PAX5-Activated SOX4.Molecular biotechnology · 2025Article
- Distinctive roles of aquaporins and novel therapeutic opportunities against cancer.RSC medicinal chemistry · 2025Review
- Mechanistic prediction and validation of Brevilin A Therapeutic effects in Lung Cancer.BMC complementary medicine and therapies · 2024Article
- Arnicolide C Suppresses Tumor Progression by Targeting 14-3-3θ in Breast Cancer.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Remodeling of tumour microenvironment: strategies to overcome therapeutic resistance and innovate immunoengineering in triple-negative breast cancer.Frontiers in immunology · 2024Review
- Sesquiterpene lactones as emerging biomolecules to cease cancer by targeting apoptosis.Frontiers in pharmacology · 2024Review
- A Review of the Research Applications ofMolecules (Basel, Switzerland) · 2023Review
- Brevilin A ameliorates sepsis-induced cardiomyopathy through inhibiting NLRP3 inflammation.Annals of medicine and surgery (2012) · 2023Article
- Moracin E and M isolated from Morus alba Linné induced the skeletal muscle cell proliferation via PI3K-Akt-mTOR signaling pathway.Scientific reports · 2023Article
- Brevilin A exerts anti-colorectal cancer effects and potently inhibits STAT3 signalingHeliyon · 2023Article
- Brevilin A inhibits RANKL-induced osteoclast differentiation and bone resorption.In vitro cellular & developmental biology. Animal · 2023Article
- Brevilin A shows an anti-tumor role in prostate cancer via the lncRNA H19/miR-194/E2F3 signaling pathway.Aging · 2023Article
- Brevilin A Inhibits VEGF-Induced Angiogenesis through ROS-Dependent Mitochondrial Dysfunction.Oxidative medicine and cellular longevity · 2022Article
- Advancing vaccine-based immunotherapy in glioblastoma treatment.Neuro-oncology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
Abstract
Brevilin A, which has anticancer activities against a range of cancers, is an abundant constituent of the medicinal herb
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.